News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Novo Nordisk A/S Diabetes Drug Tops Byetta in Trial
June 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (Reuters) - Novo Nordisk's experimental type 2 diabetes drug, liraglutide, was superior in controlling blood sugar in a clinical trial to Eli Lilly and Co and Amylin Pharmaceuticals Inc's Byetta, the Danish company said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Novo Nordisk
MORE ON THIS TOPIC
Layoffs
After Safety Stumbles, Keros Axes Pulmonary Hypertension Drug, 45% of Staff
May 30, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue
May 29, 2025
·
3 min read
·
Annalee Armstrong
Lung cancer
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings
May 29, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Moderna Loses $760M+ Government Bird Flu Contract as Vaccine Uncertainties Mount
May 29, 2025
·
2 min read
·
Tristan Manalac
